Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients
The liver is the most preferential initial site of metastasis for uveal melanoma (mUM), and this preference is associated with rapid mortality in mUM patients. Despite the significant clinical benefits of Immune checkpoint inhibitors (ICIs) in metastatic cutaneous melanoma patients, ICIs have shown...
Main Authors: | Devayani Machiraju, Jessica C. Hassel |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1068029/full |
Similar Items
-
Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
by: Masahiro Ohara, et al.
Published: (2021-03-01) -
cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
by: Nele Van Der Steen, et al.
Published: (2015-03-01) -
The Role of cMET in Gastric Cancer—A Review of the Literature
by: Filip Van Herpe, et al.
Published: (2023-03-01) -
Correlation of MET and PD-L1 Expression in Malignant Melanoma
by: Kyu Young Song, et al.
Published: (2020-07-01) -
TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma
by: Sophia B. Strobel, et al.
Published: (2022-02-01)